Literature DB >> 11313867

A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation.

J C Arevalo1, B Conde, B I Hempstead, M V Chao, D Martín-Zanca, P Pérez.   

Abstract

The TrkA NGF receptor extracellular region contains three leucine repeats flanked by cysteine clusters and two immunoglobulin-like domains that are required for specific ligand binding. Deletion of the immunoglobulin-like domains abolishes NGF binding and causes ligand independent activation of the receptor. Here we report a specific mutation that increases the binding affinity of the TrkA receptor for NGF. A change of proline 203 to alanine (P203A) in the linker region between the leucine repeats and the first Ig-like domain increased NGF binding by decreasing the ligand rate of dissociation. This mutated receptor was appropriately expressed on the cell surface and promoted ligand-independent neurite outgrowth in PC12nnr5 cells. The mutant receptor was capable of spontaneous dimerization and was constitutively phosphorylated in the absence of ligand. Moreover, expression of TrkA-P203A receptor in fibroblasts induced DNA synthesis and transformation and generated tumours in nude mice. These data suggest that domains outside of the immunoglobulin-like structure contribute to ligand binding and constitutive activation of Trk receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313867     DOI: 10.1038/sj.onc.1204215

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Structural basis of the transmembrane domain dimerization and rotation in the activation mechanism of the TRKA receptor by nerve growth factor.

Authors:  María L Franco; Kirill D Nadezhdin; Sergey A Goncharuk; Konstantin S Mineev; Alexander S Arseniev; Marçal Vilar
Journal:  J Biol Chem       Date:  2019-12-04       Impact factor: 5.157

Review 2.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

3.  A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist.

Authors:  Fouad Brahimi; Jing Liu; Andrey Malakhov; Shafinaz Chowdhury; Enrico O Purisima; Ljubica Ivanisevic; Antoine Caron; Kevin Burgess; H Uri Saragovi
Journal:  Biochim Biophys Acta       Date:  2010-06-19

4.  Deoxygedunin, a natural product with potent neurotrophic activity in mice.

Authors:  Sung-Wuk Jang; Xia Liu; Chi Bun Chan; Stefan A France; Iqbal Sayeed; Wenxue Tang; Xi Lin; Ge Xiao; Raul Andero; Qiang Chang; Kerry J Ressler; Keqiang Ye
Journal:  PLoS One       Date:  2010-07-13       Impact factor: 3.240

5.  An intracellular domain fragment of the p75 neurotrophin receptor (p75(NTR)) enhances tropomyosin receptor kinase A (TrkA) receptor function.

Authors:  Dusan Matusica; Sune Skeldal; Alex M Sykes; Nickless Palstra; Aanchal Sharma; Elizabeth J Coulson
Journal:  J Biol Chem       Date:  2013-03-07       Impact factor: 5.157

6.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Authors:  Dianjun Chen; Fouad Brahimi; Yu Angell; Yu-Chin Li; Jennifer Moscowicz; H Uri Saragovi; Kevin Burgess
Journal:  ACS Chem Biol       Date:  2009-09-18       Impact factor: 5.100

7.  A novel p75 neurotrophin receptor-related protein, NRH2, regulates nerve growth factor binding to the TrkA receptor.

Authors:  Simon S Murray; Pilar Perez; Ramee Lee; Barbara L Hempstead; Moses V Chao
Journal:  J Neurosci       Date:  2004-03-17       Impact factor: 6.167

Review 8.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

Review 9.  Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

Review 10.  Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.

Authors:  Dazhi Liu; Michael Offin; Stephen Harnicar; Bob T Li; Alexander Drilon
Journal:  Ther Clin Risk Manag       Date:  2018-07-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.